Hypersensitivity reaction in the course of acitnic keratosis treatment – case report
DOI:
https://doi.org/10.20883/jofa.45Keywords:
actinic keratosis, diclofenac sodium, contact allergic dermatitisAbstract
Actinic keratosis (AK) is a common skin disease caused by long-term sun exposure and typically forms on the face, neck, balding scalp, chest and shoulders. AK is characterized by the formation of keratotic macules, papules, or plaques with superficial scales on a red base. Treatment options for actinic keratosis include destructive therapies (eg, surgery, cryotherapy, photodynamic therapy [PDT], dermabrasion), topical medications (eg, diclofenac, topical fluorouracil, imiquimod, ingenol mebutate), and field ablation treatments (eg, chemical peels, laser resurfacing). The aim of this paper was to present a case of patient with AK and the allergic reaction to the 3% diclofenac sodium topical gel ( DSTG) treatment. After a few days of therapy an acute, eczematous reaction on the face was observed. The symptoms have subsided within a week after discontinuing the treatment. The patch test with 3% diclofenac sodium topical gel was performed and evaluated as positive suggesting a delayed type hypersensitivity reaction to active medication or its inactive ingredients. In case of contact allergy confirmed with PT, it is important to inform the patient on the need of future medication avoidance.
Downloads
References
Wessely A, Steeb T, Heppt F, Hornung A, Kaufmann MD, Koch EAT, Toussaint F, Erdmann M, Berking C, Heppt MV. A Critical Appraisal of Evidence- and Consensus-Based Guidelines for Actinic Keratosis. Curr Oncol. 2021;19:950–960.
de Berker D, McGregor JM, Mohd Mustapa MF, Exton LS, Hughes BR. British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017. Br J Dermatol. 2017;176:20–43.
Lesiak A. Wytyczne Brytyjskiego Towarzystwa Dermatologicznego 2017 – rogowacenie słoneczne. Lekarz POZ. 2017;3: 249–254.
Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, Cannavó A, Giménez-Arnau A, Gonçalo M, Goossens A, John SM, Lidén C, Lindberg M, Mahler V, Matura M, Rustemeyer T, Serup J, Spiewak R, Thyssen JP, Vigan M, White IR, Wilkinson M, Uter W. European Society of Contact Dermatitis guideline for diagnostic patch testing – recommendations on best practice. Contact Dermatitis. 2015;73:195–221.
Patel MJ, Ulrich C, Forschner T. Genetically determined susceptibility to COX-2 inhibitors: a report of exaggerated responders to diclofenac 3% gel in the treatment of actinic keratoses. Br J Dermatol. 2007; 156 Suppl 3:57–61.
Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res. 2003;15:1727–1730.
Adamson DJ, Frew D, Tatoud R, Wolf CR, Palmer CN. Diclofenac antagonizes peroxisome proliferator-activated receptor-gamma signaling. Mol Pharmacol. 2002;61:7–12.
Jarvis B, Figgitt DP. Topical 3% diclofenac in 2.5% hyaluronic acid gel: a review of its use in patients with actinic keratoses. Am J Clin Dermatol. 2003;4:203–213.
Gulin SJ, Chiriac A. Diclofenac-Induced Allergic Contact Dermatitis: A Series of Four Patients. Drug Saf Case Rep. 2016;3:15.
Kleyn CE, Bharati A, King CM. Contact dermatitis from 3 different allergens in Solaraze gel. Contact Dermatitis. 2004;51:215–216.
Cox F, Khalib K, Conlon N. PEG That Reaction: A Case Series of Allergy to Polyethylene Glycol. J Clin Pharmacol. 2021;61:832–835.
Moderna ChpL.
Pfizer ChpL.
Jacob SE, Stechschulte S. Eyelid dermatitis associated with balsam of Peru constituents: benzoic acid and benzyl alcohol. Contact Dermatitis. 2008;58:111–112.
